Flag of the European Union EU Clinical Trials Register Help

Clinical trials for emn

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: emn. Displaying page 1 of 1.
    EudraCT Number: 2018-002992-16 Sponsor Protocol Number: EMN17/54767414MMY3014 Start Date*: 2019-01-30
    Sponsor Name:European Myeloma Network (EMN)
    Full Title: A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) GR (Trial now transitioned) NO (Ongoing) BE (Trial now transitioned) CZ (Ongoing) DK (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004001-32 Sponsor Protocol Number: EMN27 Start Date*: 2021-01-29
    Sponsor Name: European Myeloma Network – EMN
    Full Title: A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis
    Medical condition: relapsed or refractory AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Ongoing) GR (Ongoing) NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002531-27 Sponsor Protocol Number: EMN30/64007957MMY3003 Start Date*: 2022-04-11
    Sponsor Name:European Myeloma Network (EMN)
    Full Title: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following ...
    Medical condition: Newly Diagnosed Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing) IT (Ongoing) NO (Ongoing) DE (Ongoing) DK (Ongoing) NL (Ongoing) AT (Ongoing) CZ (Ongoing) IE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003284-10 Sponsor Protocol Number: EMN28/68284528MMY3005 Start Date*: 2022-10-10
    Sponsor Name:Stichting European Myeloma Network (EMN)
    Full Title: A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethas...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) ES (Ongoing) NO (Ongoing) NL (Ongoing) CZ (Ongoing) GR (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002090-21 Sponsor Protocol Number: DEDALO Start Date*: 2019-05-16
    Sponsor Name:Fondazione EMN Italy Onlus
    Full Title: Daratumumab, pomalidomide and dexamethasone for del(17p) positive relapsed and relapsed/refractory multiple myeloma patients [DEDALO]
    Medical condition: Multiple Myeloma patients with relapsed or relapsed/refractory disease with the presence of del(17p) in the plasma cell clone
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004513-13 Sponsor Protocol Number: Isabel Start Date*: 2021-12-06
    Sponsor Name:EMN RESEARCH ITALY IMPRESA SOCIALE S.R.L.
    Full Title: ISATUXIMAB AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED MULTIPLE MYELOMA PATIENTS (Isabel Study)
    Medical condition: Relapsed Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003091-40 Sponsor Protocol Number: EMN26 Start Date*: 2020-12-04
    Sponsor Name: European Myeloma Network – EMN
    Full Title: PHASE II STUDY OF IBERDOMIDE (CC220) MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Medical condition: Newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing) NL (Ongoing) FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000432-10 Sponsor Protocol Number: 26866138MMY2084 Start Date*: 2013-05-23
    Sponsor Name:DUTCH BELGIAN COOPERATIVE GROUP FOR HEMATOLOGY ONCOLOGY - HOVON
    Full Title: A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF PROLONGED THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PAT...
    Medical condition: Patients with Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-022395-31 Sponsor Protocol Number: AC-004-EU Start Date*: 2010-10-07
    Sponsor Name:E.M.N. - EUROPEAN MYELOMA NETWORK
    Full Title: A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL...
    Medical condition: AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035227 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Ongoing) DK (Completed) GB (GB - no longer in EU/EEA) GR (Ongoing) ES (Ongoing) DE (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001618-27 Sponsor Protocol Number: EMN14/54767414MMY3013 Start Date*: 2017-05-19
    Sponsor Name:European Myeloma Network (EMN)
    Full Title: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy Wi...
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing) ES (Ongoing) BE (Ongoing) DE (Ongoing) CZ (Ongoing) DK (Completed) FR (Ongoing) NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018594-37 Sponsor Protocol Number: EMN-alloRIC2010 Start Date*: 2013-01-24
    Sponsor Name:European Myeloma Network
    Full Title: European Myeloma Network sequential phase I / phase II trial on RIC allogeneic transplantation: an optimized program for high risk relapsed patients
    Medical condition: Allogeneic transplantation for patients with multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10059041 Allogeneic peripheral haematopoietic stem cell transplant LLT
    14.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004844-32 Sponsor Protocol Number: EMN24 Start Date*: 2020-09-09
    Sponsor Name: European Myeloma Network – EMN
    Full Title: Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologo...
    Medical condition: newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) DE (Ongoing) GR (Ongoing) NL (Ongoing) BE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002089-37 Sponsor Protocol Number: EMN18 Start Date*: 2019-03-04
    Sponsor Name:EUROPEAN MYELOMA NETWORK
    Full Title: A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE II STUDY COMPARING DARATUMUMAB combined with BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE (Dara-VCd) VERSUS THE ASSOCIATION OF BORTEZOMIB-THALIDOMIDE-DEXAME...
    Medical condition: YOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE DIAGNOSIS ELIGIBLE TO THE AUTOLOGOUS TRANSMISSION OF STEM CELLS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing) GR (Ongoing) CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001142-28 Sponsor Protocol Number: PO-3887 Start Date*: 2015-12-30
    Sponsor Name:Fondazione EMN Italy Onlus
    Full Title: A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE III STUDY OF POMALIDOMIDE-DEXAMETHASONE (Pom-dex) versus POMALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE (Pom-cyclo-dex) IN MULTIPLE MYELOMA (MM) PATIENTS WH...
    Medical condition: MULTIPLE MYELOMA (MM) PATIENTS WHO EXPERIENCE BIOCHEMICAL (EARLY TREATMENT) OR CLINICAL RELAPSE (LATE TREATMENT) DURING LENALIDOMIDE MAINTENANCE TREATMENT
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000555-10 Sponsor Protocol Number: HO147 Start Date*: 2018-06-21
    Sponsor Name:HOVON Foundation
    Full Title: Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.
    Medical condition: Smoldering multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    26.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075894 Smoldering myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) NO (Ongoing) CZ (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003563-31 Sponsor Protocol Number: 26866138CAN 2021 Start Date*: 2007-03-09
    Sponsor Name:European Myeloma Network
    Full Title: Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM).
    Medical condition: Newly diagnosed Waldenstrom's macroglobulinemia (WM)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10054695 Waldenstrom's macroglobulinemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing) NL (Ongoing) ES (Ongoing) FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003265-34 Sponsor Protocol Number: EMN11/HO114 Start Date*: 2015-05-21
    Sponsor Name:HOVON Foundation
    Full Title: Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Mult...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) NL (Ongoing) CZ (Ongoing) AT (Prematurely Ended) GR (Prematurely Ended) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Apr 23 17:45:46 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA